Zhou C, et al. Alopecia Areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403–23.

Article  PubMed  Google Scholar 

Englander H, Paiewonsky B, Castelo-Soccio L. Alopecia Areata: a review of the genetic variants and Immunodeficiency Disorders Associated with Alopecia Areata. Skin Appendage Disord. 2023;9(5):325–32.

Article  PubMed  PubMed Central  Google Scholar 

Passeron T, et al. Inhibition of T-cell activity in Alopecia Areata: recent developments and new directions. Front Immunol. 2023;14:1243556.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Klemann C, et al. Clinical and immunological phenotype of patients with primary Immunodeficiency due to damaging mutations in NFKB2. Front Immunol. 2019;10:297.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sun SC. Non-canonical NF-κB signaling pathway. Cell Res. 2011;21(1):71–85.

Article  PubMed  CAS  Google Scholar 

Meissner J et al. Type-specific impacts of protein defects in pathogenic NFKB2 variants: Novel Clinical findings from 138 patients. J Allergy Clin Immunol Pract 2024 22:S2213-2198(24)01070-5.

Le Voyer T, et al. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency. Nature. 2023;623(7988):803–13.

Article  PubMed  PubMed Central  Google Scholar 

Higgins E, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551–3.

Article  PubMed  CAS  Google Scholar 

Su MA. JAK inhibition immunotherapy for APS-1. N Engl J Med. 2024;390(20):1918–21.

Article  PubMed  CAS  Google Scholar 

Wei D, et al. Efficacy and safety of different JAK inhibitors in the treatment of Alopecia Areata: a network meta-analysis. Front Immunol. 2023;14:1152513.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Westerkam LL, et al. Treatment options for Alopecia Areata in Children and adolescents. Paediatr Drugs. 2024;26(3):245–57.

Article  PubMed  Google Scholar 

Senna M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38(3):583–93.

Article  PubMed  CAS  Google Scholar 

Fischer M, et al. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: an ESID/EBMT-IEWP retrospective study. J Allergy Clin Immunol. 2024;153(1):275–e28618.

Article  PubMed  CAS  Google Scholar 

Zimmerman O, et al. Risks of Ruxolitinib in STAT1 gain-of-function-Associated severe fungal disease. Open Forum Infect Dis. 2017;4(4):ofx202.

Article  PubMed  PubMed Central  Google Scholar